Ibn Sina Pharmaceutical Industry announced a 63 percent cash dividend for the fiscal year ending June 30, 2024, its highest in seven years, as net profit rose by 10 percent to Tk 67.04 crore from Tk 60.55 crore the previous year. The company’s earnings per share (EPS) increased to Tk 21.46 from Tk 19.38, with a net asset value per share of Tk 111.94 and net operating cash flow per share of Tk 12.48. Founded in 1983, Ibn Sina is a key player in Bangladesh’s pharmaceutical sector, producing a variety of pharmaceutical and herbal medicines.
BIZDATAINSIGHTS
Bizdata Insights is a Market Insights, Data Intelligence and Business Advisory Platform
Our Solutions
Menu
Newsletter
Sign up for our newsletter now by entering your e-mail address and never miss out on the latest news and updates from our team!